Drug news
NICE does not recommend Sprycel (BMS) for CML
In final draft guidance, NICE has not recommended Sprycel (dasatinib), from BMS, as first-line treatment of Chronic Myeloid Leukaemia. The panel found that the most plausible Incremental Cost-effectiveness Ratio (ICER) for Sprycel compared with standard-dose Glivec exceeded �200,000 per QALY gained.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.